#BEGIN_DRUGCARD DB01123

# AHFS_Codes:
Not Available

# ATC_Codes:
D08AA02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Triple Dye (Brilliant Green + Gentian Violet + Proflavine Hemisulfate)

# Brand_Names:
Isoflav Base
Pro-Gen
Proflavin
Profoliol-B
Proformiphen
Profura
Progarmed
Progesic

# CAS_Registry_Number:
92-62-6

# ChEBI_ID:
8452

# Chemical_Formula:
C13H11N3

# Chemical_IUPAC_Name:
acridine-3,6-diamine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents, Local
Anti-Infectives, local

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.83

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
5E+005 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Proflavine

# HET_ID:
PRL

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2

# InChI_Key:
InChIKey=WDVSHHCDHLJJJR-UHFFFAOYSA-N

# Indication:
Topical antiseptic used mainly in wound dressings.

# KEGG_Compound_ID:
C11181

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1123

# Mechanism_Of_Action:
Proflavine acts by interchelating DNA (intercalation), thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands. This prevents bacterial reproduction.

# Melting_Point:
285 °C

# Molecular_Weight_Avg:
209.2465

# Molecular_Weight_Mono:
209.095297367

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164748742

# Pharmacology:
Proflavine is an acriflavine derivative which is a disinfectant bacteriostatic against many gram-positive bacteria. Proflavine is toxic and carcinogenic in mammals and so it is used only as a surface disinfectant or for treating superficial wounds.

# Predicted_LogP_Hydrophobicity:
2.1

# Predicted_LogS:
-3.3

# Predicted_Water_Solubility:
1.04e-01 g/l

# Primary_Accession_No:
DB01123

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
7099

# PubChem_Substance_ID:
46505401

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00535

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:55 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Proflavine

# pKa_Isoelectric_Point:
8.06 (at 20 °C)

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19364280	Sinha R, Hossain M, Kumar GS: Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
19894617	Berezniak EG, gladkovskaia NA, Khrebtova AS, Dukhopel'nikov EV, Zinchenko AV: [Features of binding of proflavine to DNA at different DNA-ligand concentration ratios] Biofizika. 2009 Sep-Oct;54(5):805-12.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
1711542	Sie P, Bezeaud A, Dupouy D, Archipoff G, Freyssinet JM, Dugoujon JM, Serre G, Guillin MC, Boneu B: An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme. J Clin Invest. 1991 Jul;88(1):290-6.
4857231	Koehler KA, Magnusson S: The binding of proflavin to thrombin. Arch Biochem Biophys. 1974 Jan;160(1):175-84.
6722124	Sonder SA, Fenton JW 2nd: Proflavin binding within the fibrinopeptide groove adjacent to the catalytic site of human alpha-thrombin. Biochemistry. 1984 Apr 10;23(8):1818-23.
7407200	Valeri AM, Wilson SM, Feinman RD: Reaction of antithrombin with proteases. Evidence for a specific reaction with papain. Biochim Biophys Acta. 1980 Aug 7;614(2):526-33.
7837275	De Cristofaro R, De Candia E, Picozzi M, Landolfi R: Conformational transitions linked to active site ligation in human thrombin: effect on the interaction with fibrinogen and the cleavable platelet receptor. J Mol Biol. 1995 Jan 27;245(4):447-58.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
F2

# Drug_Target_2_GenBank_ID_Gene:
M17262

# Drug_Target_2_GenBank_ID_Protein:
339641

# Drug_Target_2_GeneCard_ID:
F2

# Drug_Target_2_Gene_Name:
F2

# Drug_Target_2_Gene_Sequence:
>1869 bp
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG

# Drug_Target_2_General_Function:
Involved in blood clotting cascade

# Drug_Target_2_General_References:
10051558	Guinto ER, Caccia S, Rose T, Futterer K, Waksman G, Di Cera E: Unexpected crucial role of residue 225 in serine proteases. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1852-7.
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1349838	Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M: Detection of a single base substitution of the gene for prothrombin Tokushima. The application of PCR-SSCP for the genetic and molecular analysis of dysprothrombinemia. Int J Hematol. 1992 Feb;55(1):93-100.
1354985	Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S: Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry. 1992 Aug 25;31(33):7457-62.
1421398	Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K: Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337-->Thr and Arg-388-->His). Blood. 1992 Nov 1;80(9):2275-80.
2374926	Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW 2nd: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990 Jul 20;249(4966):277-80.
2583108	Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J: The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989 Nov;8(11):3467-75.
266717	Walz DA, Hewett-Emmett D, Seegers WH: Amino acid sequence of human prothrombin fragments 1 and 2. Proc Natl Acad Sci U S A. 1977 May;74(5):1969-72.
2719946	Henriksen RA, Mann KG: Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry. 1989 Mar 7;28(5):2078-82.
2825773	Degen SJ, Davie EW: Nucleotide sequence of the gene for human prothrombin. Biochemistry. 1987 Sep 22;26(19):6165-77.
3242619	Henriksen RA, Mann KG: Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382. Biochemistry. 1988 Dec 27;27(26):9160-5.
3567158	Miyata T, Morita T, Inomoto T, Kawauchi S, Shirakami A, Iwanaga S: Prothrombin Tokushima, a replacement of arginine-418 by tryptophan that impairs the fibrinogen clotting activity of derived thrombin Tokushima. Biochemistry. 1987 Feb 24;26(4):1117-22.
3759958	Rabiet MJ, Blashill A, Furie B, Furie BC: Prothrombin fragment 1 X 2 X 3, a major product of prothrombin activation in human plasma. J Biol Chem. 1986 Oct 5;261(28):13210-5.
3771562	Rabiet MJ, Furie BC, Furie B: Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273. J Biol Chem. 1986 Nov 15;261(32):15045-8.
3801671	Inomoto T, Shirakami A, Kawauchi S, Shigekiyo T, Saito S, Miyoshi K, Morita T, Iwanaga S: Prothrombin Tokushima: characterization of dysfunctional thrombin derived from a variant of human prothrombin. Blood. 1987 Feb;69(2):565-9.
6305407	Degen SJ, MacGillivray RT, Davie EW: Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry. 1983 Apr 26;22(9):2087-97.
6405779	Board PG, Shaw DC: Determination of the amino acid substitution in human prothrombin type 3 (157 Glu leads to Lys) and the localization of a third thrombin cleavage site. Br J Haematol. 1983 Jun;54(2):245-54.
7792730	Degen SJ, McDowell SA, Sparks LM, Scharrer I: Prothrombin Frankfurt: a dysfunctional prothrombin characterized by substitution of Glu-466 by Ala. Thromb Haemost. 1995 Feb;73(2):203-9.
7865694	James HL, Kim DJ, Zheng DQ, Girolami A: Prothrombin Padua I: incomplete activation due to an amino acid substitution at a factor Xa cleavage site. Blood Coagul Fibrinolysis. 1994 Oct;5(5):841-4.
8071320	Rydel TJ, Yin M, Padmanabhan KP, Blankenship DT, Cardin AD, Correa PE, Fenton JW 2nd, Tulinsky A: Crystallographic structure of human gamma-thrombin. J Biol Chem. 1994 Sep 2;269(35):22000-6.
873923	Butkowski RJ, Elion J, Downing MR, Mann KG: Primary structure of human prethrombin 2 and alpha-thrombin. J Biol Chem. 1977 Jul 25;252(14):4942-57.
9214615	van de Locht A, Bode W, Huber R, Le Bonniec BF, Stone SR, Esmon CT, Stubbs MT: The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. EMBO J. 1997 Jun 2;16(11):2977-84.

# Drug_Target_2_HGNC_ID:
HGNC:3535

# Drug_Target_2_HPRD_ID:
01488

# Drug_Target_2_ID:
54

# Drug_Target_2_Locus:
11p11-q12

# Drug_Target_2_Molecular_Weight:
70037

# Drug_Target_2_Name:
Prothrombin

# Drug_Target_2_Number_of_Residues:
622

# Drug_Target_2_PDB_ID:
1HAG

# Drug_Target_2_Pathway:
Abciximab Pathway	SMP00265
Acenocoumarol Pathway	SMP00269
Acetylsalicylic Acid Pathway	SMP00083
Alteplase Pathway	SMP00280
Aminocaproic Acid Pathway	SMP00286
Anistreplase Pathway	SMP00281
Aprotinin Pathway	SMP00288
Ardeparin Pathway	SMP00275
Argatroban Pathway	SMP00276
Bivalirudin Pathway	SMP00277
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Dicumarol Pathway	SMP00270
Dipyridamole (Antiplatelet) Pathway	SMP00264
Enoxaparin Pathway	SMP00272
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274
Lepirudin Pathway	SMP00278
Meloxicam Pathway	SMP00106
Phenprocoumon Pathway	SMP00271
Reteplase Pathway	SMP00285
Rofecoxib Pathway	SMP00087
Streptokinase Pathway	SMP00282
Tenecteplase Pathway	SMP00283
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Tranexamic Acid Pathway	SMP00287
Urokinase Pathway	SMP00284
Valdecoxib Pathway	SMP00116
Warfarin Pathway	SMP00268
Ximelagatran Pathway	SMP00279

# Drug_Target_2_Pfam_Domain_Function:
PF00051	Kringle
PF00089	Trypsin
PF00594	Gla

# Drug_Target_2_Protein_Sequence:
>Prothrombin precursor
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE

# Drug_Target_2_Reaction:
Selective cleavage of Arg!Gly bonds in fibrinogen to form fibrin and release fibrinopeptides A and B INHIBITOR Benzamidine; D-Phe-Pro-Arg-CH2Cl; Nalpha-(2-naphthyl-sulfonyl-glycyl)-D-p-amidinopheyl-alanylpiperadin e; Argatroban

# Drug_Target_2_Signals:
1-24

# Drug_Target_2_Specific_Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C

# Drug_Target_2_SwissProt_ID:
P00734

# Drug_Target_2_SwissProt_Name:
THRB_HUMAN

# Drug_Target_2_Synonyms:
Activated Factor II [IIa]
Coagulation factor II
EC 3.4.21.5
Prothrombin precursor
Thrombin

# Drug_Target_2_Theoretical_pI:
5.70

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X56628

# Drug_Target_3_GenBank_ID_Protein:
46660

# Drug_Target_3_GeneCard_ID:
qacR

# Drug_Target_3_Gene_Name:
qacR

# Drug_Target_3_Gene_Sequence:
>1545 bp
CTGATTTCATTTTTTACAAAAACTACTGATATGATGACATCAAAAAAAAGATGGACTGCA
CTAGTAGTATTAGCTGTTAGTTTGTTTGTTGTTACAATGGATATGACAATATTAATTATG
GCTTTACCGGAATTAGTAAGAGAGTTAGAGCCTTCTGGTACCCAACAGTTATGGATAGTT
GATATATACTCTCTTGTTTTAGCTGGCTTTATAATTCCATTGAGTGCCTTTGCTGATAAA
TGGGGAAGAAAAAAAGCATTATTAACTGGATTTGCTTTATTTGGCCTCGTTTCATTAGCT
ATATTTTTCGCAGAAAGTGCAGAGTTCGTAATAGCTATTCGATTTTTACTTGGTATTGCA
GGTGCTTTAATAATGCCAACTACCCTTTCAATGATAAGAGTAATTTTTGAAAACCCTAAA
GAAAGGGCCACTGCATTAGCTGTATGGTCAATCGCTTCATCGATAGGTGCTGTTTTTGGA
CCAATTATCGGAGGAGCTTTACTTGAGCAATTTTCATGGCACTCGGCATTTTTAATTAAT
GTACCGTTTGCGATAATAGCAGTTGTAGCAGGTTTATTTTTATTACCAGAGTCTAAGTTA
TCAAAAGAAAAGTCTCACTCGTGGGATATTCCTTCTACAATTTTATCAATTGCAGGCATG
ATTGGACTGGTATGGAGTATCAAAGAATTTTCAAAAGAAGGACTAGCAGATATTATTCCA
TGGGTTGTAATAGTATTAGCAATTACCATGATAGTGATATTTGTTAAACGTAATTTATCA
AGTTCTGATCCAATGTTAGACGTAAGACTTTTTAAAAAGAGATCATTTTCAGCTGGTACA
ATTGCTGCATTTATGACAATGTTTGCAATGGCATCTGTTTTGTTATTAGCTTCACAATGG
TTACAGGTTGTGGAAGAACTTTCTCCTTTTAAAGCTGGCTTATACCTATTACCTATGGCA
ATAGGAGATATGGTGTTTGCACCAATTGCACCCGGATTAGCGGCGCGATTTGGACCGAAA
ATAGTGTTACCTTCCGGAATTGGAATTGCAGCCATTGGCATGTTTATTATGTATTTCTTT
GGTCATCCATTATCATATTCTACAATGGCTTTAGCATTAATTTTAGTTGGAGCTGGTATG
GCTTCACTAGCAGTTGCATCTGCTCTAATAATGTTAGAAACACCTACATCAAAAGCAGGT
AATGCAGCTGCTGTTGAAGAGTCTATGTATGACCTTGGAAATGTTTTTGGTGTAGCAGTA
CTTGGTAGCCTATCTTCTATGCTTTATCGTGTATTTTTAGATATTTCATCTTTTTCATCA
AAAGGTATAGTTGGAGATTTAGCTCATGTAGCTGAAGAATCTGTAGTGGGCGCTGTCGAA
GTAGCTAAAGCTACGGGGATAAAACAGCTTGCAAACGAGGCTGTAACATCATTTAATGAT
GCTTTTGTAGCAACTGCTTTAGTAGGTGGGATTATCATGATTATCATTTCAATAGTTGTC
TATTTGTTAATTCCCAAATCACTTGATATAACTAAACAAAAATAG

# Drug_Target_3_General_Function:
Transcription

# Drug_Target_3_General_References:
11717268	Grkovic S, Brown MH, Schumacher MA, Brennan RG, Skurray RA: The staphylococcal QacR multidrug regulator binds a correctly spaced operator as a pair of dimers. J Bacteriol. 2001 Dec;183(24):7102-9.
11739955	Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, Brennan RG: Structural mechanisms of QacR induction and multidrug recognition. Science. 2001 Dec 7;294(5549):2158-63.
11867549	Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, Brennan RG: Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR. EMBO J. 2002 Mar 1;21(5):1210-8.
12648720	Schumacher MA, Brennan RG: Deciphering the molecular basis of multidrug recognition: crystal structures of the Staphylococcus aureus multidrug binding transcription regulator QacR. Res Microbiol. 2003 Mar;154(2):69-77.
2089219	Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA: Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar-transport proteins. Mol Microbiol. 1990 Dec;4(12):2051-62.
9660841	Grkovic S, Brown MH, Roberts NJ, Paulsen IT, Skurray RA: QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA. J Biol Chem. 1998 Jul 17;273(29):18665-73.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6461

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
22174.2

# Drug_Target_3_Name:
HTH-type transcriptional regulator qacR

# Drug_Target_3_Number_of_Residues:
188

# Drug_Target_3_PDB_ID:
1QVU

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00440	TetR_N
PF08360	TetR_C_5

# Drug_Target_3_Protein_Sequence:
>HTH-type transcriptional regulator qacR
MNLKDKILGVAKELFIKNGYNATTTGEIVKLSESSKGNLYYHFKTKENLFLEILNIEESK
WQEQWKKEQIKCKTNREKFYLYNELSLTTEYYYPLQNAIIEFYTEYYKTNSINEKMNKLE
NKYIDAYHVIFKEGNLNGEWCINDVNAVSKIAANAVNGIVTFTHEQNINERIKLMNKFSQ
IFLNGLSK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of qacA

# Drug_Target_3_SwissProt_ID:
P0A0N4

# Drug_Target_3_SwissProt_Name:
QACR_STAAU

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
8.55

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AY940437

# Drug_Target_4_GenBank_ID_Protein:
61104877

# Drug_Target_4_GeneCard_ID:
lfrR

# Drug_Target_4_Gene_Name:
lfrR

# Drug_Target_4_Gene_Sequence:
>570 bp
ATGACCAGCCCGAGCATCGAGAGCGGCGCGCGTGAACGCACACGTCGCGCGATCCTTGAT
GCCGCCATGCTGGTCCTGGCCGATCACCCCACCGCCGCACTCGGCGACATCGCCGCGGCC
GCCGGGGTCGGACGCAGCACGGTGCACCGCTACTACCCGGAGCGCACCGACCTGCTGCGC
GCGCTGGCCCGCCACGTCCACGACCTGAGCAACGCCGCGATCGAGCGCGCCGACCCGACC
AGCGGTCCTGTCGACGCCGCGCTGCGCCGGGTCGTCGAGAGCCAGCTCGACCTGGGCCCG
ATCGTGCTGTTCGTCTACTACGAGCCCTCGATCCTGGCCGATCCTGAACTCGCGGCCTAC
TTCGACATCGGGGACGAGGCCATCGTCGAGGTGCTCAACCGCGCGTCGACCGAGAGGCCC
GAATATCCCCCAGGGTGGGCGCGACGGGTGTTCTGGGCACTGATGCAGGCCGGTTATGAG
GCAGCCAAGGACGGCATGCCGCGTCACCAGATCGTCGACGCCATCATGACCAGCCTGACC
TCGGGCATCATCACCCTGCCGCGCACCTGA

# Drug_Target_4_General_Function:
Transcription

# Drug_Target_4_General_References:
15215089	Li XZ, Zhang L, Nikaido H: Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004 Jul;48(7):2415-23.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6828

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
20618.2

# Drug_Target_4_Name:
TetR family transcriptional repressor LfrR

# Drug_Target_4_Number_of_Residues:
189

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00440	TetR_N

# Drug_Target_4_Protein_Sequence:
>TetR family transcriptional repressor LfrR
MTSPSIESGARERTRRAILDAAMLVLADHPTAALGDIAAAAGVGRSTVHRYYPERTDLLR
ALARHVHDLSNAAIERADPTSGPVDAALRRVVESQLDLGPIVLFVYYEPSILADPELAAY
FDIGDEAIVEVLNRASTERPEYPPGWARRVFWALMQAGYEAAKDGMPRHQIVDAIMTSLT
SGIITLPRT

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Q58L87

# Drug_Target_4_SwissProt_Name:
Q58L87_MYCSM

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
5.28

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB01123
